ClinicalTrials.gg
CompletedNCT04424290HORNBILLUpdated May 22, 2024Results posted

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

A Phase 1/2 interventional study of BI 764524 and Sham control of BI 764524 in Diabetic Retinopathy, sponsored by Boehringer Ingelheim. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
115th of 196
45 · median 72
Started
2020
with 16 others
Phase 1/2
8 of 267
none open now
Registered
166th of 267
by date
Lead sponsor
4 of 267
Boehringer Ingelheim

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 115th largest by enrollment of the 196 interventional ones that give a count, is one of 17 that started in 2020, is one of 8 in phase 1/2, and was the 166th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study. The laser treatment is called panretinal photocoagulation.

The purpose of the study is to find out how well different doses of a medicine called BI 764524 are tolerated. BI 764524 is injected into the eye. The study has 2 parts. In the first part, participants get different doses of BI 764524 only once. Participants are in the first part for about 5 months and visit the study site about 8 times. In the second part, participants are put into different groups by chance. Some participants get BI 764524 injections every 4 weeks. Other participants get sham injections every 4 weeks. A sham injection means that it is not a real injection and contains no medicine. Participants cannot tell whether they get the real injection or a sham injection. For the second part, participants are in the study for about 7 months. During this time, they visit the study site about 7 times. In this study, BI 764524 is given to humans for the first time.

The doctors compare how well people tolerate the BI 764524 injections and the sham injections.

The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Single rising dose (SRD) and multiple dosing (MD) part:

  • Pan-retinal photo coagulation treated proliferative diabetic retinopathy (PDR) participants with either no or inactive retinal neovascularization per investigator judgement in the study eye
  • Male or female participants of age ≥ 18 years
  • of ≤ 12.0%
  • Women of (WOCBP) and men able to father a child must be ready and able to use two methods of with at least one of them being a highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the clinical trial protocol.

    --A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 2 years without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 2 years of menorrhea, a single FSH measurement is sufficient.

  • Signed and dated written in accordance with ICH Harmonized Guideline for Good Clinical Practice (ICH GCP) and local legislation prior to admission to the trial

SRD part only:

  • Evidence of diabetic macular ischemia (DMI) per investigator´s judgement, defined as any degree of disruption of retinal vascularity in superficial and/or deep retinal plexus in OCTA
  • Best-corrected Visual activity (VA) in the non-study eye better than best-corrected VA in the study-eye, if both eyes are eligible and have identical VA the investigator may select the study eye.
  • Best-corrected VA ≤55 letters (20/80) or worse

MD part only:

  • Presence of significant DMI: large foveal avascular zone defined as those with ≥0.5mm2 area in superficial vascular complex (SVC) present on optical coherence tomography angiography. If FAZ is \<0.5mm2 then enlarged peri-foveal inter-capillary space in at least 1 quadrant will be sufficient.
  • If both eyes are eligible, the investigator may select either eye to be the study eye.
  • Best-corrected VA ≤ 85 letters (20/20) or worse

Exclusion criteria

Exclusion Criteria:

SRD part only:

  • Participants receiving intravitreal (IVT) injections for active diabetic macular edema (DME, injections: anti-vascular endothelial growth factor (VEGF), ) and macular laser in the study eye in the previous 3 months prior to enrolment
  • Participants receiving anti-VEGF IVT injections for active PDR in the study eye in the previous 3 months prior to enrolment
  • Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol)
  • Additional eye disease in the study eye that could compromise best corrected VA (BCVA) with visual field loss, uncontrolled glaucoma (IOP>24), age related macular degeneration, history of ischemic optic neuropathy or retinal vascular occlusion, symptomatic vitreomacular traction, or genetic disorders such as retinitis pigmentosa; history of high myopia > 8 diopters in the study eye. Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with SD-OCT
  • Any intraocular surgery in the study eye within 3 months prior to screening
  • Aphakia or total absence of the posterior capsule. Yttrium aluminium garnet (YAG) laser capsulotomy in the study eye if performed less than 3 months prior to enrolment
  • Participants not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator´s opinion, makes the patient an unreliable trial participant)
  • Previous participation in this trial or in other trials with IVT injections administered within 3 months.

Further exclusion criteria apply.

MD part only:

  • DME, defined as a central subfield thickness (CST) ≥305 micrometer (μm) for men and ≥290 μm women measured with optovue (Optical coherent tomography) OCT in the study eye
  • Participants receiving IVT injections for active DME (anti-VEGF, steroids) and macular laser in the study eye in the previous 3 months prior to enrolment
  • Participants receiving anti-VEGF IVT injections for active PDR in the study eye in the previous 3 months prior to enrolment
  • Heavily lasered macula in the study eye per investigator's judgement
  • History of vitrectomy in the study eye
  • Epiretinal membrane with extended foveal contour distortion in the study eye per investigator's judgement
  • Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol) Further exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Single-rising dose part - low dose BI 764524

    Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of low dose BI 764524.

    Drug: BI 764524

  • Experimental
    Single-rising dose part - medium dose BI 764524

    Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of medium dose BI 764524.

    Drug: BI 764524

  • Experimental
    Single-rising dose part - high dose BI 764524

    Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of high dose BI 764524.

    Drug: BI 764524

  • Sham comparator
    Multiple dosing part - Sham

    Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three sham intravitreal injections, each separated by 4 weeks.

    Drug: Sham control of BI 764524

  • Experimental
    Multiple dosing part - high dose BI 764524

    Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three intravitreal injections of high dose BI 764524, each separated by 4 weeks.

    Drug: BI 764524

Interventions

  • DrugBI 764524

    BI 764524

  • DrugSham control of BI 764524

    Sham control of BI 764524

06

What researchers measure

Primary outcomes

  1. Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8

    Single-rising dose (SRD) part - The number of patients with dose limiting events (DLEs) from drug administration until Day 8 (7 days after treatment).

    Time frame: From drug administration (day 1) till day 8, Up to 7±2 days.

  2. Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.

    Multiple dosing (MD) part - the number of patients with drug-related Adverse Events (AEs) from drug administration until End of Trial.

    Time frame: From drug administration (day 1) till End of Trial, up to 23 weeks.

Secondary outcomes

  1. SRD Part - Number of Patients With Drug-related Adverse Events at End of Trial

    SRD part - Number of patients with drug-related Adverse Events at End of Trial.

    Time frame: From drug administration (day 1) till End of Trial, up to 15 weeks.

  2. SRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial

    SRD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.

    Time frame: From drug administration (day 1) till End of Trial, up to 15 weeks.

  3. MD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial

    MD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.

    Time frame: From drug administration (day 1) till End of Trial, up to 23 weeks.

  4. MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 5

    MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].

    Time frame: Baseline (day 0) and Visit 5 (day 85±7).

  5. MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 5

    MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].

    Time frame: Baseline (day 0) and Visit 5 (day 85±7).

  6. MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 7

    MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].

    Time frame: Baseline (day 0) and Visit 7 (day 155±7).

  7. MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 7

    MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].

    Time frame: Baseline (day 0) and Visit 7 (day 155±7).

  8. MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 3

    Change from baseline of best corrected visual acuity (BCVA) at Visit 3. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 3 data\].

    Time frame: Baseline (day 0) and Visit 3 (day 29±7).

  9. MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 4

    Change from baseline of best corrected visual acuity (BCVA) at Visit 4. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 4 data\].

    Time frame: Baseline (day 0) and Visit 4 (day 57±7).

  10. MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 5

    Change from baseline of best corrected visual acuity (BCVA) at Visit 5. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 5 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 5 data\].

    Time frame: Baseline (day 0) and Visit 5 (day 85±7).

  11. MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 6

    Change from baseline of best corrected visual acuity (BCVA) at Visit 6. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 6 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 6 data\].

    Time frame: Baseline (day 0) and Visit 6 (day 113±7).

  12. MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 7

    Change from baseline of best corrected visual acuity (BCVA) at Visit 7. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 7 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 7 data\].

    Time frame: Baseline (day 0) and Visit 7 (day 155±7).

  13. MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 3

    MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 3. Results calculated as \[Baseline data\]-\[Visit 3 data\].

    Time frame: Baseline (day 0) and Visit 3 (day 29±7).

  14. MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 4

    MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 4. Results calculated as \[Baseline data\]-\[Visit 4 data\].

    Time frame: Baseline (day 0) and Visit 4 (day 57±7)

  15. MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 5

    MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].

    Time frame: Baseline (day 0) and Visit 5 (day 85±7).

  16. MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 6

    MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 6. Results calculated as \[Baseline data\]-\[Visit 6 data\].

    Time frame: Baseline (day 0) and Visit 6 (day 113±7).

  17. MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 7

    MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].

    Time frame: Baseline (day 0) and Visit 7 (day 155±7).

07

Results

Posted May 22, 2024

Participant flow

This was a trial consisting of a non-randomised, uncontrolled, open label single-rising dose part and a randomised, shamcontrolled, single-blind multiple dosing part.

Participant flow — Overall Study
MilestoneSingle-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
Started3371022
Treated3361021
Completed336720
Not completed00132
Withdrew: Not treated00101
Withdrew: Adverse event00020
Withdrew: Withdrawal by subject00001
Withdrew: Other than listed00010

Outcome measures

PrimarySingle-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8

Single-rising dose (SRD) part - The number of patients with dose limiting events (DLEs) from drug administration until Day 8 (7 days after treatment).

Time frame:
From drug administration (day 1) till day 8, Up to 7±2 days.
Reported as:
Count of participants · Participants
Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8
ParticipantsSingle-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524
Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8000
PrimaryMultiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.

Multiple dosing (MD) part - the number of patients with drug-related Adverse Events (AEs) from drug administration until End of Trial.

Time frame:
From drug administration (day 1) till End of Trial, up to 23 weeks.
Reported as:
Count of participants · Participants
Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.
ParticipantsMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.02
SecondarySRD Part - Number of Patients With Drug-related Adverse Events at End of Trial

SRD part - Number of patients with drug-related Adverse Events at End of Trial.

Time frame:
From drug administration (day 1) till End of Trial, up to 15 weeks.
Reported as:
Count of participants · Participants
SRD Part - Number of Patients With Drug-related Adverse Events at End of Trial
ParticipantsSingle-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524
SRD Part - Number of Patients With Drug-related Adverse Events at End of Trial000
SecondarySRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial

SRD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.

Time frame:
From drug administration (day 1) till End of Trial, up to 15 weeks.
Reported as:
Count of participants · Participants
SRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial
ParticipantsSingle-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524
SRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial203
SecondaryMD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial

MD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.

Time frame:
From drug administration (day 1) till End of Trial, up to 23 weeks.
Reported as:
Count of participants · Participants
MD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial
ParticipantsMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial44
SecondaryMD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 5

MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].

Time frame:
Baseline (day 0) and Visit 5 (day 85±7).
Reported as:
Mean · Millimeter^2
MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 5
Millimeter^2Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 50.0167 ± 0.0197-0.0004 ± 0.0381
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -0.0234 · 95% CI -0.0558 to 0.0089Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 5

MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].

Time frame:
Baseline (day 0) and Visit 5 (day 85±7).
Reported as:
Mean · Millimeter^2
MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 5
Millimeter^2Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 50.0489 ± 0.07400.0741 ± 0.1130
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 0.0215 · 95% CI -0.0670 to 0.1100Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 7

MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].

Time frame:
Baseline (day 0) and Visit 7 (day 155±7).
Reported as:
Mean · Millimeter^2
MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 7
Millimeter^2Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 70.0133 ± 0.0152-0.0027 ± 0.0345
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -0.0109 · 95% CI -0.0412 to 0.0195Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 7

MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].

Time frame:
Baseline (day 0) and Visit 7 (day 155±7).
Reported as:
Mean · Millimeter^2
MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 7
Millimeter^2Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 70.1233 ± 0.14730.1101 ± 0.1445
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -0.0228 · 95% CI -0.1477 to 0.1021Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 3

Change from baseline of best corrected visual acuity (BCVA) at Visit 3. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 3 data\].

Time frame:
Baseline (day 0) and Visit 3 (day 29±7).
Reported as:
Mean · Number of letters
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 3
Number of lettersMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 31.5 ± 13.51.1 ± 5.2
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -1.3 · 95% CI -8.1 to 5.5Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 4

Change from baseline of best corrected visual acuity (BCVA) at Visit 4. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 4 data\].

Time frame:
Baseline (day 0) and Visit 4 (day 57±7).
Reported as:
Mean · Number of letters
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 4
Number of lettersMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 4-4.1 ± 24.41.4 ± 6.0
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 4.4 · 95% CI -7.3 to 16.2Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 5

Change from baseline of best corrected visual acuity (BCVA) at Visit 5. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 5 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 5 data\].

Time frame:
Baseline (day 0) and Visit 5 (day 85±7).
Reported as:
Mean · Number of letters
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 5
Number of lettersMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 53.9 ± 10.72.5 ± 6.5
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -3.3 · 95% CI -9.6 to 3.0Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 6

Change from baseline of best corrected visual acuity (BCVA) at Visit 6. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 6 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 6 data\].

Time frame:
Baseline (day 0) and Visit 6 (day 113±7).
Reported as:
Mean · Number of letters
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 6
Number of lettersMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 62.6 ± 9.63.1 ± 9.8
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -0.6 · 95% CI -7.3 to 6.1Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 7

Change from baseline of best corrected visual acuity (BCVA) at Visit 7. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 7 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 7 data\].

Time frame:
Baseline (day 0) and Visit 7 (day 155±7).
Reported as:
Mean · Number of letters
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 7
Number of lettersMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 74.9 ± 9.33.4 ± 7.5
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: -2.8 · 95% CI -8.7 to 3.1Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 3

MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 3. Results calculated as \[Baseline data\]-\[Visit 3 data\].

Time frame:
Baseline (day 0) and Visit 3 (day 29±7).
Reported as:
Mean · Micrometer
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 3
MicrometerMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 31.6 ± 4.90.9 ± 7.2
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 0.2 · 95% CI -4.9 to 5.4Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 4

MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 4. Results calculated as \[Baseline data\]-\[Visit 4 data\].

Time frame:
Baseline (day 0) and Visit 4 (day 57±7)
Reported as:
Mean · Micrometer
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 4
MicrometerMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 4-1.7 ± 5.10.2 ± 7.2
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 2.6 · 95% CI -2.7 to 7.9Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 5

MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].

Time frame:
Baseline (day 0) and Visit 5 (day 85±7).
Reported as:
Mean · Micrometer
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 5
MicrometerMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 5-2.9 ± 5.33.9 ± 12.8
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 7.7 · 95% CI -1.2 to 16.5Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 6

MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 6. Results calculated as \[Baseline data\]-\[Visit 6 data\].

Time frame:
Baseline (day 0) and Visit 6 (day 113±7).
Reported as:
Mean · Micrometer
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 6
MicrometerMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 6-3.0 ± 3.88.6 ± 25.1
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 13.8 · 95% CI -2.3 to 29.8Difference calculated as \[BI\]-\[Sham\].
SecondaryMD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 7

MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].

Time frame:
Baseline (day 0) and Visit 7 (day 155±7).
Reported as:
Mean · Micrometer
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 7
MicrometerMultiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 7-3.2 ± 7.43.5 ± 9.5
Statistical analysis
  • Multiple Dosing Part - Sham vs Multiple Dosing Part - High Dose BI 764524 · Adjusted mean difference: 6.8 · 95% CI -0.9 to 14.5Difference calculated as \[BI\]-\[Sham\].

Adverse events

Collected over From time of administration till the End of Trial, up to 15 weeks for the SRD part and up to 23 weeks for the MD part.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single-rising Dose Part - Low Dose BI 7645240/3 (0%)0/3 (0%)3/3 (100%)
Single-rising Dose Part - Medium Dose BI 7645240/3 (0%)0/3 (0%)1/3 (33.3%)
Single-rising Dose Part - High Dose BI 7645240/6 (0%)1/6 (16.7%)5/6 (83.3%)
Multiple Dosing Part - Sham0/10 (0%)3/10 (30%)6/10 (60%)
Multiple Dosing Part - High Dose BI 7645240/21 (0%)2/21 (9.5%)6/21 (28.6%)
Most frequent serious events
Most frequent serious events
EventSingle-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
Vitreous haemorrhageEye disorders0/30/30/62/100/21
Localised infectionInfections and infestations0/30/31/60/100/21
Peripheral vascular disorderVascular disorders0/30/31/60/100/21
Chronic kidney diseaseRenal and urinary disorders0/30/30/61/100/21
Injection site inflammationGeneral disorders0/30/30/60/101/21
Streptococcal sepsisInfections and infestations0/30/30/60/101/21
EmbolismVascular disorders0/30/30/60/101/21
Most frequent other events
Showing 10 of 25
Most frequent other events
EventSingle-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524
VertigoEar and labyrinth disorders1/30/30/60/100/21
Conjunctival haemorrhageEye disorders1/30/30/61/100/21
Ocular hyperaemiaEye disorders1/30/30/60/100/21
Vitreous detachmentEye disorders0/30/32/60/100/21
Oedema peripheralGeneral disorders1/30/30/60/100/21
Blood glucose decreasedInvestigations1/30/30/60/100/21
Intraocular pressure increasedInvestigations1/30/30/62/100/21
Lipase increasedInvestigations0/31/30/61/100/21
DizzinessNervous system disorders0/31/30/60/100/21
HypertensionVascular disorders1/30/31/60/101/21

Baseline characteristics

Treated set: all patients who were randomised and treated with at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Single-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524Total
Mean64.7 ± 15.061.0 ± 7.060.8 ± 6.060.0 ± 6.559.3 ± 13.260.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Single-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524Total
Female22251021
Male11451122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524Total
Hispanic or Latino0134210
Not Hispanic or Latino32361933
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single-rising Dose Part - Low Dose BI 764524Single-rising Dose Part - Medium Dose BI 764524Single-rising Dose Part - High Dose BI 764524Multiple Dosing Part - ShamMultiple Dosing Part - High Dose BI 764524Total
American Indian or Alaska Native000000
Asian110114
Native Hawaiian or Other Pacific Islander000000
Black or African American100034
White12691735
More than one race000000
Unknown or Not Reported000000
08

Study locations

19 sites
  • Trinity Research
    Dothan, Alabama 36301, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Stanford University Medical Center
    Palo Alto, California 94303, United States
  • Florida Retina Institute
    Orlando, Florida 32806, United States
  • Raj K. Maturi, MD PC
    Carmel, Indiana 46290, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02115, United States
  • Long Island Vitreoretinal Consultants
    Great Neck, New York 11021, United States
  • New York Eye and Ear Infirmary of Mount Sinai
    New York, New York 10003, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Austin Research Center for Retina, PLLC
    Austin, Texas 78705, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Valley Retina Institute, PA
    McAllen, Texas 78503, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 77384, United States
  • Bradford Royal Infirmary
    Bradford, BD9 6RJ, United Kingdom
  • Bristol Eye Hospital
    Bristol, BS1 2LX, United Kingdom
  • Southend University Hospital
    Essex, SS0 0RY, United Kingdom
  • Gloucestershire Royal Hospital
    Gloucester, GL1 3NN, United Kingdom
  • Moorfields Eye Hospital
    London, EC1V 2PD, United Kingdom
  • Sunderland Eye Infirmary
    Sunderland, SR2 9HP, United Kingdom
09

References and documents

Publications

  • Chong V, Nguyen QD, Sepah Y, Giani A, Pearce E. HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol. Trials. 2022 Aug 17;23(1):669. doi: 10.1186/s13063-022-06527-y. PubMed 35978329 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: https://www.mystudywindow.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Apr 2023, 34 months.

Results were first posted in May 2024, 1 year after primary completion. A results delay was requested in Jul 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2020
First posted
Jun 9, 2020
StartActual
Jun 12, 2020
Primary completionActual
Apr 28, 2023
CompletionActual
Apr 28, 2023
Results delay requested
Jul 11, 2023
Results first posted
May 22, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04424290
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Jun 12, 2020
Primary completion
Apr 28, 2023
Completion
Apr 28, 2023
Results posted
May 22, 2024
Last update
May 22, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion